{"contentid": 488754, "importid": NaN, "name": "FDA curbs use of liver drug Ocaliva on safety concerns", "introduction": "The US Food and Drug Administration announced on Wednesday that it is restricting the use of US biotech firm Intercept Pharmaceuticals\u00e2\u0080\u0099 liver disease medicine Ocaliva (obeticholic acid) in patients having primary biliary cholangitis (PBC) with advanced cirrhosis of the liver because it can cause serious harm.", "content": "<p>The US Food and Drug Administration announced on Wednesday that it is restricting the use of US biotech firm Intercept Pharmaceuticals&rsquo; (Nasdaq: ICPT) liver disease medicine Ocaliva (obeticholic acid) in patients having primary biliary cholangitis (PBC) with advanced cirrhosis of the liver because it can cause serious harm.</p>\n<p>Intercept saw its shares fall as low as $13.88 in early trading yesterday, but more than recovered, up 10% at $17.05 after the bell.</p>\n<p>Some PBC patients with cirrhosis who took Ocaliva, especially those with evidence of advanced cirrhosis, developed liver failure, sometimes requiring liver transplant. In the five years since Ocaliva&rsquo;s accelerated approval, the FDA identified 25 cases of serious liver injury leading to liver decompensation or liver failure associated with Ocaliva in PBC patients with cirrhosis, both in those without clinical signs of cirrhosis (compensated) or in those with clinical signs of cirrhosis (decompensated). Many of these PBC patients had advanced cirrhosis before starting Ocaliva.</p>\n<h2><strong>Revised Boxed Warning</strong></h2>\n<p>The FDA added a new Contraindication, FDA&rsquo;s strongest warning, to the&nbsp;<a href=\"https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDAsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTA1MjYuNDExMTEyMjEiLCJ1cmwiOiJodHRwczovL3d3dy5hY2Nlc3NkYXRhLmZkYS5nb3Yvc2NyaXB0cy9jZGVyL2RhZi9pbmRleC5jZm0_dXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPWdvdmRlbGl2ZXJ5In0.urcNJboU9QYEoswq1GPqj13SSYGYBHPnsOC5xNT-WtM/s/1255922260/br/106992422300-l\">Ocaliva prescribing information</a> and patient&nbsp;<a href=\"https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTA1MjYuNDExMTEyMjEiLCJ1cmwiOiJodHRwczovL3d3dy5hY2Nlc3NkYXRhLmZkYS5nb3YvZHJ1Z3NhdGZkYV9kb2NzL2xhYmVsLzIwMTgvMjA3OTk5czAwM2xibC5wZGY_dXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPWdvdmRlbGl2ZXJ5I3BhZ2U9MjMifQ.Hq_JUoISN7Z3wAEJT7j8AwxUj8qDz8Wd9tak_THs-WA/s/1255922260/br/106992422300-l\">Medication Guide</a>&nbsp;stating that Ocaliva should not be used in PBC patients with advanced cirrhosis. The FDA also revised the <em>Boxed Warning</em>, the agency&rsquo;s most prominent warning, to include this information along with related warnings about this risk.</p>\n<p>Based on the original clinical trials, the FDA believes the benefits of Ocaliva outweigh the risks for PBC patients who do not have advanced cirrhosis. The FDA will continue to monitor and evaluate the clinical benefit and adverse events of Ocaliva and will communicate any new information to the public if it becomes available.</p>\n<p>Ocaliva has had previous safety warnings from the agency, and a year ago, Intercept received a complete response letter from the FDA regarding its New Drug Application (NDA) for obeticholic acid (OCA) for the treatment of fibrosis due to non-alcoholic steatohepatitis (NASH).</p>", "date": "2021-05-27 10:21:00", "meta_title": "FDA curbs use of liver drug Ocaliva on safety concerns", "meta_keywords": "Intercept Pharmaceuticals. Ocaliva, Liver disease, Safety, FDA, Boxed warning", "meta_description": "FDA curbs use of liver drug Ocaliva on safety concerns", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-27 08:48:15", "updated": "2021-05-27 10:21:08", "access": NaN, "url": "https://www.thepharmaletter.com/article/fda-curbs-use-of-liver-drug-ocaliva-on-safety-concerns", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "intercept-large.jpg", "image2id": "intercept-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Nephrology and Hepatology", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "USA", "company_tag": "Intercept Pharmaceuticals", "drug_tag": "Ocaliva", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-27 10:21:00"}